A review of sitagliptin with special emphasis on its use in moderate to severe renal impairment

References

• Diabetes UK [homepage on the Internet] Available from http://www.diabetes.org.uk Accessed July 1, 2013
   Google Scholar
• González EL Johansson S Wallander MA Rodríguez LA Trends in the prevalence and incidence of diabetes in the UK: 1996–2005 J Epidemiol Community Health 2009 63 4 332 326 19240084
   PubMed Web of Science ®Google Scholar
• National Diabetes Information Clearinghouse (NDIC) National Diabetes Statistics 2011 Available from: http://diabetes.niddk.nih.gov/dm/pubs/statistics/ Accessed July 1, 2013
   Google Scholar
• Nathan DM Buse JB Davidson MB American Diabetes Association European Association for Study of Diabetes Medical management of hyperglycemia in type 2 diabetes: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 2009 32 193 203 18945920
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE) CG87 Type 2 diabetes – newer agents (a partial update of CG66): short guideline Available from: http://www.nice.org.uk/nicemedia/live/12165/44318/44318.pdf Accessed July 1, 2013
   Google Scholar
• National Kidney Foundation KDOQI clinical practice guideline for diabetes and CKD: 2012 update Am J Kidney Dis 2012 60 5 850 886 23067652
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence (NICE) CG73 Chronic kidney disease: early identification and management of chronic kidney disease in adults in primary and secondary care Available from: http://www.nice.org.uk/Guidance/CG73 Accessed July 1, 2013
   Google Scholar
• Hallan SI Coresh J Astor BC International comparison of the relationship of chronic kidney disease prevalence and ESRD risk J Am Soc Nephrol 2006 17 8 2275 2284 16790511
   PubMed Web of Science ®Google Scholar
• Coresh J Astor BC Greene T Eknoyan G Levey AS Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey Am J Kidney Dis 2003 41 1 1 12 12500213
   PubMed Web of Science ®Google Scholar
• Haroun MK Jaar BG Hoffman SC Comstock GW Klag MJ Coresh J Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland J Am Soc Nephrol 2003 14 11 2934 2941 14569104
   PubMed Web of Science ®Google Scholar
• New JP Middleton RJ Klebe B Assessing the prevalence, monitoring and management of chronic kidney disease in patients with diabetes compared with those without diabetes in general practice Diabet Med 2007 24 4 364 369 17335468
   PubMed Web of Science ®Google Scholar
• Hippisley-Cox J Coupland C Predicting the risk of chronic kidney disease in men and women in England and Wales: prospective derivation and external validation of the QKidney Scores BMC Fam Pract 2010 11 49 20565929
   PubMed Web of Science ®Google Scholar
• United States Renal Data System USRDS 2007 annual data report Bethesda, MD National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, US Department of Health and Human Services 2007
   Google Scholar
• Tonelli M Muntner P Lloyd A Alberta Kidney Disease Network Using proteinuria and estimated glomerular filtration rate classify risk in patients with chronic kidney disease. A cohort study Ann Intern Med 2011 154 12 21 21200034
   PubMed Web of Science ®Google Scholar
• Kidney Disease Improving Global Outcomes (KDIGO) 2012 clinical practice guidelines for the evaluation and management of chronic kidney disease Kidney Int Suppl 2013 3 1 150
   Web of Science ®Google Scholar
• Liang J Leung KK Lam SY Leung PS Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells Diabetes Obes Metab 2012 14 9 842 581 22519909
   PubMed Web of Science ®Google Scholar
• Brazg R Xu L Dalla Man C Cobelli C Thomas K Stein PP Effect of adding sitagliptin, a dipeptidylpeptidase-4 inhibitor, to metformin on 24-h glycemic control and beta-cell function in patients with type 2 diabetes Diabet Obes Metab 2007 9 186 193
   PubMed Web of Science ®Google Scholar
• Mu J Petrov A Eiermann GJ Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes Eur J Pharmacol 2009 623 148 154 19765579
   PubMed Web of Science ®Google Scholar
• Ahrén B Winzell MS Wierup N Sundler F Burkey B Hughes TE DPP-4 inhibition improves glucose tolerance and increases insulin and GLP-1 responses to gastric glucose in association with normalized islet topography in mice with beta-cell specific overexpression of human islet amyloid polypeptide Regul Pept 2007 143 97 103 17482289
   PubMed Web of Science ®Google Scholar
• Williams-Herman D Xu L Teng R Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes Diabetes Obes Metab 2012 14 1 67 76 22050786
   PubMed Web of Science ®Google Scholar
• Karasik A Aschner P Katzeff H Davies MJ Stein PP Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials Curr Med Res Opin 2008 24 2 489 496 18182122
   PubMed Web of Science ®Google Scholar
• Zerilli T Pyon EY Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus Clin Ther 2007 29 12 2614 2634 18201579
   PubMed Web of Science ®Google Scholar
• Drucker DJ Nauck MA The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 2006 368 1696 1705 17098089
   PubMed Web of Science ®Google Scholar
• Balas B Baig MR Watson C The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single dose administration in type 2 diabetic patients J Clin Endocrinol Metab 2007 92 1249 1255 17244786
   PubMed Web of Science ®Google Scholar
• Ahrén B Simonsson E Larsson H Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4 week study period in type 2 diabetes Diabetes Care 2002 25 869 875 11978683
   PubMed Web of Science ®Google Scholar
• Bergman A Ebel D Liu F Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers Biopharm Drug Dispos 2007 28 315 322 17575559
   PubMed Web of Science ®Google Scholar
• Ahrén B DPP-4 inhibitors Best Pract Res Clin Endocrinol Metab 2007 21 517 533 18054733
   PubMed Web of Science ®Google Scholar
• Ahrén B Dipeptidyl peptidase-4 inhibitors: clinical data and clinical implications Diabetes Care 2007 30 1344 1350 17337494
   PubMed Web of Science ®Google Scholar
• Ahrén B Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin – diabetes control and potential adverse events Best Pract Res Clin Endocrinol Metab 2009 23 487 498 19748066
   PubMed Web of Science ®Google Scholar
• JANUVIA (sitagliptin) [prescribing information] Whitehouse Station, NJ Merck and Co, Inc
   Google Scholar
• Herman GA Stevens C Van Dyck K Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses Clin Pharmacol Ther 2005 78 675 688 16338283
   PubMed Web of Science ®Google Scholar
• Herman GA Bergman A Stevens C Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes J Clin Endocrinol Metab 2006 91 4612 4619 16912128
   PubMed Web of Science ®Google Scholar
• Vincent SH Reed JR Bergman AJ Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C] sitagliptin in humans Drug Metab Dispos 2007 35 533 538 17220239
   PubMed Web of Science ®Google Scholar
• Bergman AJ Stevens C Zhou Y Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind randomized, placebo-controlled study in healthy male volunteers Clin Ther 2006 28 55 72 16490580
   PubMed Web of Science ®Google Scholar
• Herman GA Bergman A Liu F Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects J Clin Pharmacol 2006 46 876 886 16855072
   PubMed Web of Science ®Google Scholar
• Hermansen K Kipnes M Luo E Fanurik D Khatami H Stein P Sitagliptin Study 035 Group Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or in combination with metformin Diabetes Obes Metab 2007 9 733 745 17593236
   PubMed Web of Science ®Google Scholar
• Vilsbøll T Rosenstock J Yki-Järvinen H Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes Diabetes Obes Metab 2010 12 2 167 177 20092585
   PubMed Web of Science ®Google Scholar
• Aschner P Kipnes MS Lunceford JK Sanchez M Mickel C Williams-Herman DE Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes Diabetes Care 2006 29 2632 2637 17130196
   PubMed Web of Science ®Google Scholar
• Raz I Hanefeld M Xu L Caria C Williams-Herman D Khatami H Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus Diabetologia 2006 49 2564 25671 17001471
   PubMed Web of Science ®Google Scholar
• Scott R Wu L Sanchez M Stein P Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes Int J Clin Pract 2007 61 171 180 17156104
   PubMed Web of Science ®Google Scholar
• Goldstein BJ Feinglos MN Lunceford JK Johnson J Williams-Herman DE Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes Diabetes Care 2007 30 1979 1987 17485570
   PubMed Web of Science ®Google Scholar
• Qi DS Teng R Jiang M Two-year treatment with sitagliptin and initial combination therapy of sitagliptin and metformin provides substantial and durable glycemic control in patients with type 2 diabetes Diabetologia 2008 51 Suppl 1 S36
   Google Scholar
• Nonaka K Kakikawa T Sato A Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes Diabet Res Clin Pract 2008 79 291 298
   PubMed Web of Science ®Google Scholar
• Mohan V Yang W Son HY Efficacy and safety of sitagliptin inthe treatment of patients with type 2 diabetes in China, India and Korea Diab Res Clin Pract 2009 83 106 116
   PubMed Web of Science ®Google Scholar
• Hanefeld M Herman GA Wu M Mickel C Sanchez M Stein PP Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes Curr Med Res Opin 2007 23 6 1329 1339 17559733
   PubMed Web of Science ®Google Scholar
• Inzucchi SE Bergenstal RM Buse JB Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care 2012 35 1364 1379 22517736
   PubMed Web of Science ®Google Scholar
• Charbonnel B Karasik A Liu J Wu M Meininger G Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone Diabetes Care 2006 29 2638 2643 17130197
   PubMed Web of Science ®Google Scholar
• Scott R Loeys T Davies MJ Engel SS Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes Diabetes Obes Metab 2008 10 959 969 18201203
   PubMed Web of Science ®Google Scholar
• Nauck MA Meininger G Sheng D Terranella L Stein PP Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial Diabet Obes Metab 2007 9 194 205
   PubMed Web of Science ®Google Scholar
• Seck T Nauck M Sheng D Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study Int J Clin Pract 2010 64 5 562 576 20456211
   PubMed Web of Science ®Google Scholar
• Lim S An JH Shin H Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study Clin Endocrinol (Oxf) 2012 77 2 215 223 21955147
   PubMed Web of Science ®Google Scholar
• Pérez-Monteverde A Seck T Xu L Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs pioglitazone in drug-naïve patients with type 2 diabetes Int J Clin Pract 2011 65 9 930 938 21849007
   PubMed Web of Science ®Google Scholar
• Olansky L Reasner C Seck TL A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycemic control versus metformin monotherapy due to a low rate of addition of antihyperglycemic agents Diabetes Obes Metab 2011 13 9 841 849 21535346
   PubMed Web of Science ®Google Scholar
• Rosenstock J Brazg RG Andryuk PJ Lu K Stein P Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study Clinical Ther 2006 28 1556 1568 17157112
   PubMed Web of Science ®Google Scholar
• Arjona Ferreira JC Dobs A Goldstein BJ Triple combination therapy with sitagliptin, metformin and rosiglitazone improves glycemic control in patients with type 2 diabetes Diabetologia 2008 51 Suppl 1 S365
   Google Scholar
• Fonseca V Staels B Morgan JD2nd Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes J Diabetes Complications 2013 27 2 177 183 23116881
   PubMed Web of Science ®Google Scholar
• Bergman AJ Cote C Yi B Effect of renal insufficiency on the pharmacokinetics of MK-0431 (sitagliptin), a selective dipeptidyl-peptidase-IV (DPP-IV) inhibitor Clin Pharmacol Ther 2006 79 75
   Web of Science ®Google Scholar
• Bergman AJ Cote C Yi B Effect of Renal Insufficiency on the Pharmacokinetics of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor Diabetes Care 2007 30 7 1862 1864 17468348
   PubMed Web of Science ®Google Scholar
• Chan JC Scott R Arjona Ferreira JC Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency Diabetes Obes Metab 2008 10 7 545 555 18518892
   PubMed Web of Science ®Google Scholar
• Arjona Ferreira JC Marre M Barzilai N Efficacy and safety of sitagliptin versus glipizide in patients with type 2 diabetes and moderate-to-severe chronic renal insufficiency Diabetes Care 2013 36 5 1067 1073 23248197
   PubMed Web of Science ®Google Scholar
• Arjona Ferreira JC Corry D Mogensen CE Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial Am J Kidney Dis 2013 61 4 579 587 23352379
   PubMed Web of Science ®Google Scholar
• Patil HR Al Badarin FJ Al Shami HA Meta-analysis of effect of dipeptidyl peptidase-4 inhibitors on cardiovascular risk in type 2 diabetes mellitus Am J Cardiol 2012 110 826 833 22703861
   PubMed Web of Science ®Google Scholar
• Eurich DT Simpson S Senthilselvan A Asche CV Sandhu-Minhas JK McAlister FA Comparative safety and effectiveness of sitagliptin in patients with type 2 diabetes: retrospective population based cohort study BMJ 2013 346 2 10
   Web of Science ®Google Scholar